Welcome to our dedicated page for 908 Devices news (Ticker: $MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 908 Devices's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 908 Devices's position in the market.
Rhea-AI Summary
908 Devices and Terumo Blood and Cell Technologies announce a collaboration to enable on-line monitoring of critical process parameters in Terumo BCT’s Quantum Flex Cell Expansion System. The collaboration aims to improve manufacturing efficiency and reduce costs in cell and gene therapy development. 908 Devices' MAVEN analyzer will be integrated into the Quantum Flex system to provide real-time monitoring and control of key process parameters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
-
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) will participate in investor conferences including the 53rd Annual Baird Industrial Conference, Stifel Healthcare Conference 2023, and 25th Annual Stephens Investment Conference. The conferences will feature in-person presentations and fireside chats. Interested parties can access live and archived webcasts on the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
-
News
Rhea-AI Summary
908 Devices Inc. has been awarded $10.4 million in purchase orders from the U.S. Air Force and Air National Guard for its MX908 handheld mass spectrometry device with Aero module. The Aero module enables quick detection of chemical threats. The MX908 device is used to detect drugs, chemical agents, and explosives at trace levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
Rhea-AI Summary
908 Devices Inc. to report Q3 2023 financial results on November 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
-
Rhea-AI Summary
908 Devices Inc. enters initial production phase of AVCAD program with partner Smiths Detection, producing 122 systems. The AVCAD is a next-generation chemical detector for the U.S. Department of Defense, featuring the company's HPMS technology. This validates 908 Devices' technology as a new standard for chemical detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
-
News
Rhea-AI Summary
908 Devices launches MAVERICK, an optical in-line analyzer for bioprocess control using Raman spectroscopy. MAVERICK offers real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures without complex modeling. It provides rich process fingerprint data and can monitor up to six bioreactor modules simultaneously. MAVERICK aims to enhance process understanding and implement dynamic control strategies for faster time to market and more efficient processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
Rhea-AI Summary
908 Devices Inc. (Nasdaq: MASS) to participate in Gilmartin Group Emerging Growth Company Showcase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
-
Rhea-AI Summary
908 Devices reports 9% increase in revenue for Q2 2023, driven by 27% growth in handheld revenue. Recurring revenue increases by 39% YoY. Net loss of $9.3 million for Q2 2023. Cash, cash equivalents, and marketable securities at $153 million as of June 30, 2023. Full year 2023 revenue expected to be in the range of $49 million to $52 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.01%
Tags
-
Rhea-AI Summary
908 Devices Inc (Nasdaq: MASS) announces that Tennessee law enforcement agencies have chosen to implement the MX908 handheld mass spectrometer to enhance drug identification processes. The pilot program aims to decrease the quantity of controlled substance samples sent to the laboratory, reducing wait times and expediting the judicial process. The MX908's capabilities enable law enforcement officers to ensure individuals prosecuted for drug-related offenses enter drug treatment programs much sooner.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
908 Devices Inc.
Nasdaq:MASS
MASS Rankings
MASS Stock Data
193.78M
24.68M
7.52%
86.42%
3.5%
Other Measuring and Controlling Device Manufacturing
Manufacturing
United States of America
BOSTON
About MASS
908 devices, is democratizing chemical analysis by way of mass spectrometry, offering point-of-need chemical analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. these purpose-built and user-centric devices serve a range of industries including safety and security, oil & gas, life sciences and other applied markets. 908 devices is headquartered in the heart of boston where they research, design and manufacture innovative products based on high pressure mass spectrometry (hpms).